All News

Testing will now be possible for those who cannot get to a collection center, including those who are home because they are ill, quarantined, or at high risk of infection due to their age or comorbidities. A Rutgers official said the new method will allow for a dramatic increase in the number of people who can be tested.

This week, the top managed care news included FDA grants emergency use authorization to COVID-19 treatment; dapagliflozin’s new approval breaks ground in SGLT2 competition; and AJMC® gets an inside look at how The Michael J. Fox Foundation is assisting the Parkinson community during the pandemic.

Guidelines created by the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) address care management and treatment options for patients with psoriasis in relation to the increased risk of developing inflammatory, cardiovascular, and metabolic conditions.

Lupin Pharmaceuticals Inc. (Lupin) announced positive results from its phase 3 trial assessing the efficacy and safety of secnidazole (Solosec) in female patients with trichomoniasis. Although trichomoniasis is common in the United States, the risk of being infected with the infection is nearly 10 times higher for African American women compared with non-Hispanic white women.

A new test, supported by an artificial intelligence (AI) algorithm, can detect glaucoma progression a year and a half earlier than widely used optical coherence tomography retinal imaging technology, according to a study published in Expert Review of Molecular Diagnostics.